670 related articles for article (PubMed ID: 27795431)
1. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
2. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
[TBL] [Abstract][Full Text] [Related]
3. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
Rao PG; Lambert GS; Upadhyay C
J Virol; 2023 Sep; 97(9):e0071023. PubMed ID: 37681958
[TBL] [Abstract][Full Text] [Related]
4. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
[TBL] [Abstract][Full Text] [Related]
5. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.
Ko SY; Pegu A; Rudicell RS; Yang ZY; Joyce MG; Chen X; Wang K; Bao S; Kraemer TD; Rath T; Zeng M; Schmidt SD; Todd JP; Penzak SR; Saunders KO; Nason MC; Haase AT; Rao SS; Blumberg RS; Mascola JR; Nabel GJ
Nature; 2014 Oct; 514(7524):642-5. PubMed ID: 25119033
[TBL] [Abstract][Full Text] [Related]
6. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.
Sagar M; Akiyama H; Etemad B; Ramirez N; Freitas I; Gummuluru S
J Infect Dis; 2012 Apr; 205(8):1248-57. PubMed ID: 22396600
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.
Moog C; Dereuddre-Bosquet N; Teillaud JL; Biedma ME; Holl V; Van Ham G; Heyndrickx L; Van Dorsselaer A; Katinger D; Vcelar B; Zolla-Pazner S; Mangeot I; Kelly C; Shattock RJ; Le Grand R
Mucosal Immunol; 2014 Jan; 7(1):46-56. PubMed ID: 23591718
[TBL] [Abstract][Full Text] [Related]
8. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.
Forthal DN; Gilbert PB; Landucci G; Phan T
J Immunol; 2007 May; 178(10):6596-603. PubMed ID: 17475891
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
Frankel SS; Steinman RM; Michael NL; Kim SR; Bhardwaj N; Pope M; Louder MK; Ehrenberg PK; Parren PW; Burton DR; Katinger H; VanCott TC; Robb ML; Birx DL; Mascola JR
J Virol; 1998 Dec; 72(12):9788-94. PubMed ID: 9811714
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells.
Chomont N; Hocini H; Gody JC; Bouhlal H; Becquart P; Krief-Bouillet C; Kazatchkine M; Bélec L
Virology; 2008 Jan; 370(2):246-54. PubMed ID: 17920650
[TBL] [Abstract][Full Text] [Related]
11. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.
Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N
Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3.
Suphaphiphat K; Tolazzi M; Hua S; Desjardins D; Lorin V; Dereuddre-Bosquet N; Mouquet H; Scarlatti G; Grand RL; Cavarelli M
EBioMedicine; 2020 Jul; 57():102842. PubMed ID: 32619962
[TBL] [Abstract][Full Text] [Related]
13. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
[TBL] [Abstract][Full Text] [Related]
14. Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.
Hioe CE; Li G; Liu X; Tsahouridis O; He X; Funaki M; Klingler J; Tang AF; Feyznezhad R; Heindel DW; Wang XH; Spencer DA; Hu G; Satija N; Prévost J; Finzi A; Hessell AJ; Wang S; Lu S; Chen BK; Zolla-Pazner S; Upadhyay C; Alvarez R; Su L
PLoS Pathog; 2022 Jan; 18(1):e1010183. PubMed ID: 34986207
[TBL] [Abstract][Full Text] [Related]
15. VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice.
Sun M; Li Y; Yuan Z; Lu W; Kang G; Fan W; Li Q
Arch Virol; 2016 Sep; 161(9):2449-55. PubMed ID: 27343044
[TBL] [Abstract][Full Text] [Related]
16. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.
Perez LG; Costa MR; Todd CA; Haynes BF; Montefiori DC
J Virol; 2009 Aug; 83(15):7397-410. PubMed ID: 19458010
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.
Pace CS; Song R; Ochsenbauer C; Andrews CD; Franco D; Yu J; Oren DA; Seaman MS; Ho DD
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13540-5. PubMed ID: 23878231
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.
Tudor D; Derrien M; Diomede L; Drillet AS; Houimel M; Moog C; Reynes JM; Lopalco L; Bomsel M
Mucosal Immunol; 2009 Sep; 2(5):412-26. PubMed ID: 19587640
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.
Anand SP; Ding S; Tolbert WD; Prévost J; Richard J; Gil HM; Gendron-Lepage G; Cheung WF; Wang H; Pastora R; Saxena H; Wakarchuk W; Medjahed H; Wines BD; Hogarth M; Shaw GM; Martin MA; Burton DR; Hangartner L; Evans DT; Pazgier M; Cossar D; McLean MD; Finzi A
J Virol; 2021 Aug; 95(18):e0079621. PubMed ID: 34232070
[TBL] [Abstract][Full Text] [Related]
20. Fc receptor-mediated antiviral antibodies.
Forthal DN; Moog C
Curr Opin HIV AIDS; 2009 Sep; 4(5):388-93. PubMed ID: 20048702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
